Disease Overview：Fluorescence in Situ Hybridization（FISH）
Fluorescence in situ hybridization (FISH) is not a disease but a highly sensitive molecular cytogenetic diagnostic technique widely used in hematology to detect chromosomal abnormalities—including deletions, translocations, amplifications, and gene rearrangements—in hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. Unlike conventional karyotyping, FISH enables targeted interrogation of specific genomic loci using fluorescently labeled DNA probes, offering superior resolution for detecting cryptic or submicroscopic aberrations—even in non-dividing cells—making it indispensable for accurate risk stratification, treatment selection, and minimal residual disease monitoring. Its clinical utility extends to confirming diagnoses, predicting therapeutic response (e.g., *TP53* deletion in CLL), and guiding targeted therapies like BTK inhibitors or venetoclax-based regimens.
China offers compelling advantages for international patients seeking FISH testing and integrated hematologic care. Leading academic hospitals—such as Peking Union Medical College Hospital and Ruijin Hospital—employ state-of-the-art automated FISH platforms (e.g., Leica Biosystems’ BOND RX, Abbott’s mFISH), validated per CAP/CLIA-equivalent standards, with turnaround times averaging 3–5 working days. Chinese hematologists contribute to global clinical trials and routinely manage complex cases involving high-risk cytogenetics, with published outcomes demonstrating comparable sensitivity (>98%) and specificity to Western benchmarks. Crucially, comprehensive FISH panels—including dual-fusion, break-apart, and multi-target assays—cost 40–60% less than in the US or EU, without compromising analytical rigor or clinical interpretation. As a dedicated medical tourism agency, we facilitate seamless access: coordinating appointments with certified hematopathology labs, providing itemized, upfront pricing in USD/EUR, arranging visa support, accredited interpreter services, and post-test clinical consultations—all tailored to international patient needs and regulatory expectations.
Medical Treatment Guide
# Treatment Options & Itemized Cost Breakdown: Fluorescence In Situ Hybridization (FISH) Testing — Hematology Department
Note: FISH is a *diagnostic molecular cytogenetic assay*, not a treatment. It detects chromosomal abnormalities (e.g., *BCR::ABL1*, *PML::RARA*, *IGH* translocations, del(5q), del(17p)) in hematologic malignancies (AML, ALL, CML, MDS, multiple myeloma). All costs reflect real 2024 Grade 3A hospital pricing in China, converted at ¥7.2/$1.
Non-Surgical / Diagnostic / Laboratory Options
Standard FISH Panel (Single-Target)
- •Indications: Suspected CML (t(9;22)), APL (t(15;17)), or isolated cytogenetic follow-up
- •Specimen: Bone marrow aspirate (preferred) or peripheral blood (if high blast count ≥20%)
- •Fee Breakdown:
- Probe hybridization (1 target: e.g., *BCR::ABL1*): $122 - Slide preparation & fluorescence microscopy analysis (≥200 interphase nuclei): $89 - Pathologist interpretation & report: $67 - Total per target: $296
Extended FISH Panel (Multi-Target)
- •Indications: Newly diagnosed AML/MDS, therapy-related disease, or complex karyotype suspicion
- •Probes included: *TP53* (17p), *CEBPA*, *RUNX1*, *ETV6*, *RB1*, *D13S319* (13q) — up to 6 probes
- •Fee Breakdown:
- Each additional probe (+1–3): $94 - Automated imaging & digital quantification (mandatory for ≥4 probes): $118 - Total (6-probe panel): $706
Procedural / Interventional Options
*No surgical intervention is associated with FISH testing.* Bone marrow aspiration (required for optimal specimen) is a minimally invasive diagnostic procedure—not a therapeutic intervention—and is billed separately:
- •BM aspiration + biopsy (hematology department): $154
- •Pre-procedure labs (CBC, coagulation panel, hepatitis B/C serology): $47
- •Local anesthesia & sterile setup: $22
- •Total procedural package: $223
Special/Complex Condition Testing
- •Sequential FISH + NGS Integration (e.g., FISH for *IGH* translocation + RNA-seq for fusion partners in MM):
- Targeted RNA sequencing (21-gene fusion panel): $385 - Integrated bioinformatics & clinical correlation report: $132 - Total: $929
- •Repeat FISH post-induction therapy (monitoring MRD in AML): $296 (same as standard single-target)
Quick Selection Guide
- •Newly diagnosed elderly AML patient (≥75 y, comorbidities): Opt for standard 3-probe FISH panel ($412) + BM aspiration ($223); avoids costly NGS unless high-risk morphology.
- •Young ALL patient requiring rapid risk stratification: Choose extended 6-probe FISH ($706)—covers *ETV6::RUNX1*, *BCR::ABL1*, *KMT2A* rearrangements critical for protocol assignment.
- •Budget-constrained patient (<$300): Prioritize single-target FISH ($296) only if clinical suspicion is highly specific (e.g., classic CML presentation).
- •Relapsed/refractory MDS with suspected 5q-/17p-: Extended panel ($706) is cost-effective vs. sequential single tests; includes *TP53* and *RPS14* probes essential for lenalidomide eligibility.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Fluorescence in Situ Hybridization Medical Vacation Packages
Curated transparent all-inclusive packages combining Fluorescence in Situ Hybridization treatment with China top medical destinations:
